PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
Celine Johanna van de LaarMartijn A H Oude VoshaarPeter Ten KloosterDanyta I TedjoReinhard BosTim L Th A JansenA WillemzeGrada A VersteegY P M Goekoop-RuitermanEric-Jan KrootMart van de LaarPublished in: RMD open (2024)
Up to present, in a T2T setting, patients with RA failing csDMARDs have two main strategies to consider, Janus Kinases inhibitor versus bDMARDs (in clinical practice, predominantly TNFi). The PERFECTRA study suggested that starting with baricitinib was superior over TNFi in achieving response at 12 weeks and resulted in improved outcomes across all studied clinical measures and PROMs throughout the study duration in these patients.